Syndax Pharmaceuticals, Inc. (SNDX)
8.72
-0.41
(-4.49%)
USD |
NASDAQ |
Nov 20, 16:00
8.73
+0.01
(+0.11%)
After-Hours: 20:00
Syndax Pharmaceuticals Gross Profit (TTM) : 267.12M for Sept. 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 267.12M |
| June 30, 2026 | 241.59M |
| March 31, 2026 | 208.69M |
| December 31, 2025 | 165.62M |
| September 30, 2025 | 106.46M |
| June 30, 2025 | 75.19M |
| March 31, 2025 | 38.51M |
| December 31, 2024 | 19.35M |
| September 30, 2024 | 12.49M |
| June 30, 2024 | -0.009M |
| March 31, 2024 | -0.161M |
| December 31, 2023 | -0.271M |
| September 30, 2023 | -0.383M |
| June 30, 2023 | -0.488M |
| March 31, 2023 | -0.446M |
| December 31, 2022 | -0.454M |
| September 30, 2022 | 126.12M |
| June 30, 2022 | 126.22M |
| March 31, 2022 | 126.33M |
| December 31, 2021 | 126.46M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | -0.004M |
| June 30, 2016 | -0.004M |
| March 31, 2016 | -0.008M |
| September 30, 2014 | -0.012M |
| June 30, 2014 | -0.008M |
| March 31, 2014 | -0.014M |
| December 31, 2013 | -0.01M |
| September 30, 2013 | -0.006M |
| March 31, 2013 | -0.006M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.088B |
| Emergent BioSolutions, Inc. | 254.10M |
| Incyte Corp. | 5.502B |
| Vertex Pharmaceuticals, Inc. | 11.15B |
| Travere Therapeutics, Inc. | 588.71M |